All entries for: Antiviral

August 6, 2026

Emergent Biosolutions

Layoffs

Gaithersburg, Maryland

501-1,000 employees

“To align resourcing to current needs, Emergent BioSolutions is restructuring its business, a move that includes letting go of 93 employees across the company and eliminating 21 vacant positions. Emergent announced the plans in its second quarter earnings release and provided additional details in a related SEC filing.

The layoffs represent a small number of the company’s overall workforce, which was about 900 employees as of Dec. 31, 2025.

Emergent, which develops and manufactures medicines for diseases including smallpox and makes Narcan, which treats opioid overdoses, did not specify which locations the workforce reduction will affect. However, the announcement noted the closure of wet laboratories in Gaithersburg, Maryland, where the company is based.

The restructuring includes eliminating the role of chief medical officer, head of research and development, pushing Simon Lowry out of Emergent effective Aug. 19. The company is also creating a new “growth organization” that combines research and development, business development and strategy into one function. Stephanie Duatschek will lead that team in her new role as executive vice president, chief growth officer. Previously, she was senior vice president, chief global strategy and franchise development officer.

Emergent expects to incur costs of $10 million to $11.5 million in connection with the restructuring. As of June 30, the company’s capital resources included $139.7 million in cash and cash equivalents.”

Disease Area: Antiviral, Infectious Diseases

Drug Type: Biologic, Small Molecule

Source

August 5, 2026

Pfizer - New York

Layoffs

New York, NY

10,000+ employees

“Pfizer is adding $2.5 billion in cuts to an ongoing restructuring, with much of the new reduction coming from technology and simplification efforts across the New York pharma’s commercial, R&D and manufacturing functions.

The cuts under Pfizer’s Realigning Our Cost Base Program are expected to save $1 billion, the company announced Aug. 4 in its second-quarter earnings release. Most savings will occur between 2027 and 2029, but not for free: the program carries a one-time cost of $2 billion for digital enablement, implementation and severance.

A company spokesperson declined to give further details on how severance will be paid, whether any jobs will be affected, or what technological changes are planned.”

Disease Area: Antiviral, Cardiology, Dermatology, Gastrointestinal, Immune Diseases, Infectious Diseases, Metabolic Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

July 29, 2026

GSK/England

Layoffs

London, England

10,000+ employees

“GSK’s $2.5 billion restructuring over the next three years will include global job cuts, the company announced in a July 29 media call. CEO Luke Miels declined to say how many employees the U.K. pharma will let go, saying he wanted his team to discuss the changes with staff first and would provide an update once the plans are implemented. He framed the effort as a reallocation toward new medicines.

GSK intends to use part of the expected savings to keep funding its late-stage portfolio and pipeline. Some will also go toward improving margins and profitability ahead of the 2028 U.S. patent expiry for its HIV medicine dolutegravir.”

Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source

May 8, 2026

Gildead Sciences

Layoffs

Foster City, CA

10,000+ employees

In the wake of closing its $7.8 billion Arcellx acquisition last week, Gilead Sciences is gutting the biotech’s workforce in California and Maryland, laying off 192 employees total. Given Arcellx had 220 employees as of March 1, according to an SEC filing last month, the cuts are likely wiping out 87% of the staff.

The largest cuts are happening at the biotech’s headquarters in Redwood City, California. Gilead is letting go of 108 employees at that site effective June 30, according to a Worker Adjustment and Retraining Notification (WARN) notice. The pharma is also laying off 84 people in Rockville, Maryland. Those cuts are taking place over a longer period, from June 30, 2026, to April 30, 2027, according to a WARN notice.

Both notices were dated April 30, two days after Gilead announced it had completed its acquisition of Arcellx, making the biotech a wholly owned subsidiary.

Disease Area: Antiviral, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

May 7, 2026

Gilead Sciences, Inc.

Negative Outlook

Foster City, CA

10,000+ employees

While the full impact of the IRA on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the IRA will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.

Disease Area: Antiviral, Chronic Disease, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

May 6, 2026

Gilead Sciences

Layoffs

Foster City, CA

10,000+ employees

After closing its $7.8 billion takeover of Arcellx last week, Gilead Sciences is now letting go of 108 employees at the biotech’s headquarters in Redwood City, California, according to a Worker Adjustment and Retraining Notification (WARN) alert for the state. The layoffs will take effect on June 30.

Arcellx had 220 employees as of March 1, according to a securities filing last month, indicating that Gilead’s cuts will nearly halve the biotech’s workforce.

Gilead and Arcellx are long-time partners. The companies joined hands in December 2022, with the pharma paying $225 million upfront alongside a $100 million equity investment in the biotech. The deal was focused on Arcellx’s late-stage CAR T therapy—the asset that would later be named anito-cel—for the treatment for relapsed or refractory multiple myeloma. Gilead at the time pledged up to $3.9 billion in milestones.

Disease Area: Antiviral, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

March 23, 2026

Arbutus Biopharma Corp/PA

Negative Outlook

Warminster, PA

51-200 employees

The IRA also created a drug price negotiation program under which the prices for certain Medicare units of certain high Medicare spend drugs and biologicals without generic or biosimilar competition are capped by reference to, among other things, a specified non-federal average manufacturer price starting in 2026. Failure to comply with requirements under the drug price negotiation program is subject to an excise tax and/or a civil monetary penalty. This or any other legislative change could impact the market conditions for our product candidates.

Disease Area: Antiviral, Infectious Diseases

Drug Type: Biologic

Source

March 19, 2026

Assembly Biosciences

Neutral Outlook

South San Francisco, CA

51-200 employees

For example, the Inflation Reduction Act of 2022 (IRA) enacted on August 16, 2022, seeks to reduce prescription drug costs by, among other provisions, allowing Medicare to negotiate prices for certain high-cost prescription drugs in Medicare Parts B and D, imposing an excise tax on pharmaceutical manufacturers that refuse to negotiate pricing with Medicare, and requiring inflation rebates to limit annual drug price increases in Medicare. These provisions began taking effect progressively starting in 2023, and, in January 2026, CMS announced the 15 drugs selected for the third cycle of Medicare drug price negotiations. Beginning in 2025, the IRA also eliminated the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and imposing a new manufacturer discount program. However, various industry stakeholders, including certain pharmaceutical companies and industry trade organizations have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional.

Disease Area: Antiviral, Infectious Diseases

Drug Type: Small Molecule

Source

March 12, 2026

Precision Biosciences Inc

Neutral Outlook

Durham, NC

51-200 employees

While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Antiviral, Hematology, Immune Diseases, Infectious Diseases, Neurological Diseases, Rare Diseases

Drug Type: Biologic

Source

March 5, 2026

GSK plc

Negative Outlook

London, England

10,000+ employees

In ovarian cancer, Zejula saw a decrease in sales, driven by ongoing volume reductions, including impacts of an FDA labelling update restricting use to certain patient populations, and the impacts of IRA Medicare Part D redesign in the US

Disease Area: Antiviral, Chronic Disease, Gastrointestinal, Hematology, Immune Diseases, Infectious Diseases, Metabolic Diseases, Oncology, Respiratory Diseases

Drug Type: Biologic, Small Molecule

Source